Trial Profile
A Prospective, Single-center, Open-Label, Phase II Study of Abraxane in Patients With Visceral Metastases Dominant Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Feb 2022
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 25 Feb 2021 Status changed from recruiting to completed.
- 13 Feb 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
- 21 Jan 2018 Planned end date changed from 1 Feb 2019 to 1 Dec 2019.